Ventana Medical Systems, Inc. is the pharma partner of choice for Companion Diagnostics, empowering you to deliver personalized healthcare to patients worldwide.

Skip to Content

Companion diagnostics

For every 10 cancer patients treated, an average of only half will benefit. For some, the treatment won't have any effect; others may suffer from serious side effects.1 Ventana Medical Systems, Inc. (Ventana) is working at our industry's forefront to change this dynamic by customizing therapy to individual patients, helping you to improve diagnostic accuracy, lab efficiency and patient safety.

In collaboration with leading pharmaceutical companies, we identify and develop innovative companion diagnostics to target those patients who are likely to respond to specific therapies. Because we recognize the tremendous potential for these solutions, we continue to focus on addressing unmet medical needs by developing the cutting-edge tools you need.

You can be confident that VENTANA products, only from Roche, are the right solution to empower you to deliver the highest-quality diagnostic information for patients — today and in the future.

A global leader in tissue-based cancer diagnostics, we provide a premier end-to-end offering, with expertise at every stage from discovery to commercialization. Working together under one roof, Ventana and pharma increase the efficiency and speed of developing patient selection biomarkers.

  • Brings 180+ biomarker projects with a strong track record — reliably on time and on budget
  • Reduces biotech companies' development and commercialization risks
  • Provides global access through the Ventana and Roche commercial network and installed base
  • Offers a differentiated, broad instrument and reagent portfolio

INFORM HER2 Dual ISH Probe Cocktail Assay

In the news

Companion diagnostics from Ventana continues to make news in the industry. Check back for updates and links to companion diagnostics' articles and information.

Click here to learn more

Tissue diagnostics: no other technology captures the anatomical context that helps determine patient outcomes and enables Personalized Healthcare:

  • Companion tissue tests help determine the best course of treatment
  • We are committed to expanding our market-leading HER2 diagnostic franchise
  • The VENTANA ALK IHC Rabbit Monoclonal Primary Antibody* aids in early detection and treatment decisions for non-small cell lung cancer patients

*The VENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody is not available for use in the United States. Check with your local Account Manager for the availability of products in your region and the applicable intended use.

Related Links

"We see an enormous potential and huge opportunities in PHC. Targeted therapies and diagnostic tests that help to improve medical decision making not only offer clinical benefits for patients but are also attractive through health economic benefits to regulatory authorities and payers."
— Severin Schwan, CEO Roche

1. Source: Roche Personalized Healthcare brochure, 2011